Need Help?

Pediatric Papillary Thyroid Carcinoma RNA-Seq

38 PPTCs were sequenced using RNASeq to identify oncogenic variants in driver-unknown tumors and to explore gene expression patterns. RNA libraries were quantified by qPCR using the Kapa Library Quantification Illumina/ABI Prism Kit protocol (KAPA Biosystems). Libraries were pooled in equimolar quantities and paired-end sequenced on 2 lanes of a High Throughput Run Mode flowcell with the V4 sequencing chemistry on an Illumina HiSeq 2500 platform following Illumina’s recommended protocol to generate paired-end reads of 126-bases in length.

Request Access

Sickkids policy

DATA ACCESS AGREEMENT These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions. Definitions Authorised Personnel: The individuals at the User Institution to whom Shlien Lab, at The Hospital for Sick Children grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorised Personnel are set out in Appendix II. Data: The managed access datasets to which the User Institution has requested access. Data Producers: Shlien Lab, at The Hospital for Sick Children and the collaborators listed in Appendix I responsible for the development, organisation, and oversight of these Data. External Collaborator: A collaborator of the User, working for an institution other than the User Institution. Project: The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II. Publications: Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Research Participant: An individual whose data form part of these Data. Research Purposes: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research. User: The principal investigator for the Project. User Institution(s): The Hospital for Sick Children 1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify EGA within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify EGA prior to any significant changes to the protocol for the Project. 14. The User Institution will notify EGA as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. EGA may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than EGA. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00005188285 1617934449708 5.1 GB
EGAF00005188286 1617933177880 5.3 GB
EGAF00005188287 1617933177880 5.3 GB
EGAF00005188288 1617933066817 5.5 GB
EGAF00005188289 1617936152162 6.0 GB
EGAF00005188290 1617938854569 6.1 GB
EGAF00005188291 1617933666959 4.9 GB
EGAF00005188292 1617932715951 5.0 GB
EGAF00005188293 1617933177880 4.8 GB
EGAF00005188294 1617932916462 4.9 GB
EGAF00005188295 1617949851538 7.0 GB
EGAF00005188296 1617943135218 6.5 GB
EGAF00005188297 1617949138796 6.9 GB
EGAF00005188298 1617945704771 6.5 GB
EGAF00005188299 1617975678653 11.5 GB
EGAF00005188300 1617977730576 11.7 GB
EGAF00005188301 1617935221551 5.0 GB
EGAF00005188302 1617932916462 4.8 GB
EGAF00005188303 1617933414097 4.8 GB
EGAF00005188304 1617932916462 4.8 GB
EGAF00005188305 1617931847021 3.8 GB
EGAF00005188306 1617931025657 3.9 GB
EGAF00005188307 1627251040342 4.5 GB
EGAF00005188308 1627251040342 4.6 GB
EGAF00005188309 1617932566856 4.8 GB
EGAF00005188310 1617933529675 4.9 GB
EGAF00005188311 1617930788490 3.7 GB
EGAF00005188312 1617931472191 3.8 GB
EGAF00005188313 1617932916462 4.9 GB
EGAF00005188314 1617933177880 5.0 GB
EGAF00005188315 1617931605975 4.5 GB
EGAF00005188316 1617934264538 4.6 GB
EGAF00005188317 1617935819769 5.6 GB
EGAF00005188318 1617934264538 5.6 GB
EGAF00005188319 1617934449708 5.1 GB
EGAF00005188320 1617933066817 5.2 GB
EGAF00005188321 1617931744498 4.2 GB
EGAF00005188322 1617931949351 4.3 GB
EGAF00005188323 1617932077267 4.7 GB
EGAF00005188324 1617932077267 4.7 GB
EGAF00005188325 1617933666959 4.0 GB
EGAF00005188326 1617930917750 3.9 GB
EGAF00005188327 1617934741673 4.7 GB
EGAF00005188328 1617932916462 4.8 GB
EGAF00005188329 1617931847022 4.4 GB
EGAF00005188330 1617932214814 4.6 GB
EGAF00005188331 1617931847021 4.6 GB
EGAF00005188332 1617935819769 4.7 GB
EGAF00005188333 1617934975921 4.4 GB
EGAF00005188334 1617932077267 4.6 GB
EGAF00005188335 1617932566856 3.9 GB
EGAF00005188336 1617931247519 4.0 GB
EGAF00005188337 1617932077267 4.4 GB
EGAF00005188338 1617932566856 4.5 GB
EGAF00005188339 1617934264538 4.6 GB
EGAF00005188340 1617931744498 4.5 GB
EGAF00005188341 1617931247519 4.3 GB
EGAF00005188342 1617931632551 4.3 GB
EGAF00005188343 1617931744498 4.3 GB
EGAF00005188344 1617932077267 4.4 GB
EGAF00005188345 1617932214814 4.1 GB
EGAF00005188346 1617932214814 4.3 GB
EGAF00005188347 1617931247519 4.1 GB
EGAF00005188348 1617932077267 4.1 GB
EGAF00005188349 1617935221551 5.0 GB
EGAF00005188350 1617933177880 5.1 GB
EGAF00005188351 1627251040342 4.0 GB
EGAF00005188352 1617931605975 4.1 GB
EGAF00005188353 1617932077267 4.2 GB
EGAF00005188354 1617934864207 4.4 GB
EGAF00005188355 1617931744498 4.6 GB
EGAF00005188356 1617932460817 4.7 GB
EGAF00005188357 1617931605974 4.5 GB
EGAF00005188358 1617932214814 4.6 GB
EGAF00005188359 1617935466111 5.9 GB
EGAF00005188360 1617938250297 6.0 GB
76 Files (376.6 GB)